Table 2 Clinical course comparison of MBC and TN-IDC groups during follow-up
MBC (n = 81) | TN-IDC (n = 162) | P | |
|---|---|---|---|
Recurrence | 0.11 | ||
( +) | 18(22%) | 23(14%) | |
( −) | 63(78%) | 139(86%) | |
Death | 0.05 | ||
( +) | 17(21%) | 19(12%) | |
( −) | 64(79%) | 143(88%) | |
Local recurrence | 1 | ||
( +) | 1(1%) | 3(2%) | |
( −) | 80(99%) | 159(98%) | |
Organ metastasis | 0.03 | ||
( +) | 17(21%) | 17(10%) | |
( −) | 64(79%) | 145(90%) | |
Brain metastasis | 0.91 | ||
( +) | 3(4%) | 8(5%) | |
( −) | 78(96%) | 154(95%) | |
Lung metastasis | 0.008 | ||
( +) | 12(15%) | 8(5%) | |
( −) | 69(85%) | 154(95%) | |
Liver metastasis | 1 | ||
( +) | 4(5%) | 8(5%) | |
( −) | 77(95%) | 154(95%) | |
Bone metastasis | 0.03 | ||
( +) | 7(9%) | 3(2%) | |
( −) | 74(91%) | 159(98%) | |
Bone marrow metastasis | 1 | ||
( +) | 1(1%) | 1(1%) | |
( −) | 80(99%) | 161(99%) | |
Pleural metastasis | |||
( +) | 2(3%) | 0 | |
( −) | 79(97%) | 162 | |